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Leptomeningeal metastases (LM) from solid tumors are de-
scribed in approximately 10% of patients with solid tumors. It 
is the third most common metastatic complication affecting 
the nervous system after brain metastases and epidural me-
tastases. For both the assessment of the prognosis of LM pa-
tients and outcome to treatment, quantification of LM disease 
burden is important. By imaging alone this is quite difficult, as 
LM exhibit both solid and nonsolid growth patterns and can be 
present in multiple anatomical compartments.
In this issue of Neuro-Oncology, Nevel et  al present their 
report on a retrospective quantitative assessment of disease 
burden in patients with LM from non-small-cell lung cancer 
(NSCLC).1
The purpose of their interesting study was to determine 
whether radiographic disease burden assessment and modern 
cerebrospinal fluid (CSF) analysis can be employed to pre-
dict survival. They reviewed charts and MRI scans of 171 pa-
tients with LM of NSCLC from a quaternary cancer center, the 
Memorial Sloan Kettering Cancer Center. Eighty-four patients 
(49%) had a targetable mutation. Radiographic involvement 
of LM was scored in 8 predefined locations on gadolinium-
enhanced MRI scans in 76 bevacizumab-naïve patients with 
complete staging. In 16 patients, circulating tumor cells (CTCs) 
in CSF were quantified, and cell-free tumor DNA measure-
ments in CSF were done in 21 patients. Extent of radiographic 
involvement of LM was found to be significantly correlated with 
shorter survival. CTC number in CSF was a borderline signifi-
cant prognostic indicator (P = 0.048) for a shorter survival and 
cell-free DNA concentration in CSF showed a trend (P = 0.06) 
toward a statistical significant prognosticator for shorter sur-
vival. Therefore, both the extent of radiological involvement of 
LM and advanced CSF diagnostics appear to have value for the 
assessment of the prognosis of NSCLC patients with LM.
The study by Nevel et al is of particular interest, as the treat-
ment of NSCLC patients is changing rapidly. Specific driver 
gene alterations in NSCLC patients have led to the develop-
ment of targeted therapy with tyrosine kinase inhibitors. 
Epidermal growth factor receptor (EGFR) activating mutations 
and anaplastic lymphoma kinase (ALK) translocations are 
found in 25% of NSCLC patients, and in an additional minority 
of NSCLC patients BRAF or ROS mutations or MET or human 
EGFR 2 (HER2) amplifications are being detected.2
The use of EGFR and ALK inhibitors has significantly im-
proved the clinical outcome of NSCLC patients, including 
those with central nervous system metastases, like LM. In the 
BLOOM study, the response rate was 62% (95% CI: 45–78%) 
with a response duration of 15.2  months (95% CI: 7.5–17.5 
mo) in patients with LM from EGFR-mutated NSCLC patients 
treated with osimertinib, a third-generation, brain-penetrating 
EGFR inhibitor.3 Similarly, the ASCEND-7 trial showed re-
sponse of LM in patients with ALK-translocated NSCLC when 
treated with the ALK inhibitor ceritinib, even after prior failure 
to crizotinib.4 Thus, for treatment monitoring, assessment of 
LM is becoming increasingly important.
For the radiographic part of assessing the LM disease 
burden, Nevel et al scored the MRI scans by using 8 prede-
fined anatomic locations: cerebrum, ventricle, brainstem, cere-
bellum, cranial nerves, and cervical, thoracic, and lumbosacral 
spinal cord. Patients received one point per location of radio-
graphically evident LM. An MRI review was done by 3 neuro-
oncologists. When there was disagreement about the number 
of MRI sites of LM disease between the original radiology re-
port and one of the neuro-oncologists, consensus was reached 
by the 3 neuro-oncologists.
The difficulties of the quantification of LM on MRI were 
nicely demonstrated by the Response Assessment in Neuro-
Oncology (RANO) group on LM. In a report from this group, 
a complex RANO-LM scoring card was used to score LM 
of solid tumors in 22 patients at baseline and after treat-
ment. The interobserver variability between the 19 raters 
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(neuroradiologists and neurologists) was so high that this 
scoring system clearly cannot be used as a response tool 
in LM. A  new simplified RANO-LM score is now under 
construction. 5 Can the MR score of Nevel et al be used in-
stead of the RANO-LM criteria? Their MRI score appears 
straightforward and was found to correlate with outcome. 
However, its interobserver variability and whether it is a 
useful tool to monitor LM response need to be determined 
and validated in independent datasets.
Besides, with MR imaging, LM can by assessed by CSF 
analysis. Classically, the diagnostic golden standard for 
LM was cytology, by demonstrating intra-CSF tumor cells. 
More advanced CSF techniques consist of CTC detection 
and cell-free DNA analysis. Furthermore, if a driver muta-
tion is present in the parental tumor, driver mutation anal-
ysis in the CSF can be performed. This latter technique was 
successfully used in the BLOOM study as the EGFR mutant 
DNA copy number appeared to be a promising response 
evaluation tool for LM in EGFR-mutated NSCLC.6 For CTC 
enumeration of epithelial tumors in CSF, 2 different tech-
niques can be used ie, rare cell capture technology and im-
mune flow cytometry assay which both apply antibodies 
against epithelial cell adhesion molecule (EpCAM). These 
CTC techniques show a sensitivity for the diagnosis of LM 
of 76–100% and a specificity of 84–100%.7
Nevel et  al used the rare cell capture technology to 
detect CTC in CSF. They were the first to show that the 
CTC number in CSF has prognostic value (CTC  ≥50/mL 
vs <50/mL) in a small patient group (n  =  16). They also 
showed that the cell-free DNA concentration in CSF 
(>0.02 vs <0.02 ng/mL), as determined by targeted exome 
sequencing, shows a trend toward having a significant 
prognostic value in LM (n = 21).
An important benefit of CTC enumeration, cell-free DNA 
analysis, or driver mutation copy analysis in CSF is that 
these CSF assays are quantitative. Therefore, they have the 
future potential to obviate the need for subjective MR quan-
tification of subtle leptomeningeal abnormalities and their 
changes upon therapy. Moreover, the value of all of these 
advanced CSF techniques depends on how well they cor-
relate with patient benefit, represented by absence of clin-
ical progression and overall survival. In other words, upon 
the validation of the surrogacy of both the laboratory and 
imaging endpoint, their prognostic value should be deter-
mined. This is one of the key elements of the Nevel study.
Can the MRI and CSF assessments be used to evaluate 
LM activity over time, to monitor disease outcome to 
treatment? To address this question, the authors propose 
a prospective study to validate the prognostic and thera-
peutic response value of radiographic and advanced CSF 
techniques in LM. This may help us to better and earlier 
understand the effect of novel treatments on this disease. 
In order to speed up this evaluation process, multicenter 
collaboration but more importantly standardized and ac-
cepted techniques for advanced CSF assays will be crucial.
Acknowledgments
The text is the sole product of the authors; no third party had 
input or gave support to its writing.
Conflict of interest statement. M.J.B.vd.B: honoraria 
from Cellgene, Carthera, Abbvie, Boehringer, Bayer, Genenta, 
Nerviano. D.B. has none.
References
1. Nevel KS, DiStefano N, Lin X, et al. A retrospective, quantitative assess-
ment of disease burden in patients with leptomeningeal metastases 
from non-small-cell lung cancer. Neuro-Oncol. 2020;22(5):675–683.
2. Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the 
critical role of immunohistochemical markers in the subclassification of 
non-small cell lung carcinoma (NSCLC): moving from targeted therapy to 
immunotherapy. Semin Cancer Biol. 2018;52(Pt 1):103–109.
3. Yang JCH, Kim S-W, Kim D-W, et al. Osimertinib in patients with ep-
idermal growth factor receptor mutation-positive non-small-cell lung 
cancer and leptomeningeal metastases: the BLOOM study. J Clin Oncol. 
2020;38(6):538–547.
4. Barlesi F, Kim D-W, Bertino EM, et al. Efficacy and safety of ceritinib in 
ALK-positive non-small cell lung cancer (NSCLC) patients with leptome-
ningeal metastases (LM): results from the phase II, ASCEND-7 study. Ann 
Oncol. 2019;30(Supplement_5):v143–v158. doi: 10.1093/annonc/mdz243.
5. Le  Rhun  E, Devos  P, Boulanger  T, et  al; European Organisation for 
Research and Treatment of Cancer (EORTC) Brain Tumor Group (BTG) 
Central Nervous System (CNS) Metastases Committee and the EORTC 
BTG Imaging Committee. The RANO leptomeningeal metastasis group 
proposal to assess response to treatment: lack of feasibility and clinical 
utility and a revised proposal. Neuro Oncol. 2019;21(5):648–658.
6. Ahn MJ, Kim DW, Cho BC, et al. Activity and safety of AZD3759 in EGFR-
mutant non-small-cell lung cancer with CNS metastases (BLOOM): a 
phase 1, open-label, dose-escalation and dose-expansion study. Lancet 
Respir Med. 2017;5(11):891–902.
7. van  Bussel  MTJ, Pluim  D, Bol  M, Beijnen  JH, Schellens  JHM, 
Brandsma D. EpCAM-based assays for epithelial tumor cell detection in 
cerebrospinal fluid. J Neurooncol. 2018;137(1):1–10.
D
ow
nloaded from
 https://academ
ic.oup.com
/neuro-oncology/article-abstract/22/5/592/5801057 by Erasm
us U
niversiteit R
otterdam
 user on 15 July 2020
